NanoMed

NanoMed is a Sydney-based nanobiotechnology company focused on the development and commercialization of colloidal nanomedicines for oncology. The company's proprietary platform transforms conventional, water-soluble chemotherapeutic agents into lipophilic prodrugs that self-assemble into stable, targeted nanoparticles. This approach aims to improve the efficacy-to-toxicity ratio by selectively delivering high payloads of drugs like 5-fluorouracil (5-FU) and gemcitabine directly to cancer cells while minimizing systemic side effects. NanoMed is currently advancing its lead programs through preclinical development and is seeking partnerships to transition into human clinical trials.